









Markets
/
Stocks
/
nasdaq-abos
/

Acumen Pharmaceuticals Inc

ABOS

2.400USD

+0.150+6.67%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

145.38MMarket Cap

LossP/E TTM



Acumen Pharmaceuticals Inc

2.400

+0.150+6.67%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Acumen Pharmaceuticals Inc

Currency: USD Updated: 2026-02-06

Key Insights

Acumen Pharmaceuticals Inc's fundamentals are relatively weak, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 77 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 7.00.In the medium term, the stock price is expected to trend up.Despite strong stock market performance and technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Acumen Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

77 / 392

Overall Ranking

198 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Acumen Pharmaceuticals Inc Highlights

StrengthsRisks

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a disease-modifying approach to target underlying cause of Alzheimer's disease (AD). The Company is focused on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), in its Phase II ALTITUDE-AD clinical trial following Phase I results in early AD patients (patients with mild cognitive impairment or mild dementia due to AD). Sabirnetug is a recombinant humanized immunoglobulin gamma 2 (IgG2), monoclonal antibody (mAb) that selectively targets the anti-amyloid-beta oligomer, has demonstrated functional and protective effects in in-vitro assays, and has demonstrated in-vivo safety and pharmacologic activity in multiple animal species including transgenic mouse models for AD. The Company is developing sabirnetug for IV administration once every four weeks (Q4W) for the treatment of early AD, and it has developing sabirnetug for subcutaneous administration.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Fairly Valued

The company’s latest PE is -1.09, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 38.36M shares, increasing 0.00% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 1.65M shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.32.

Analyst Rating

Based on 6 analysts

Strong Buy

Current Rating

7.000

Target Price

+211.11%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Acumen Pharmaceuticals Inc is 5.54, ranking 351 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

5.54

Change



Financials

2.04

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.86

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.04

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Acumen Pharmaceuticals Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Acumen Pharmaceuticals Inc is 8.83, ranking 13 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.09, which is -57.12% below the recent high of -0.47 and -685.62% above the recent low of -8.54.

Score

Industry at a Glance

Previous score

8.83

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 77/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Acumen Pharmaceuticals Inc is 9.33, ranking 5 out of 392 in the Biotechnology & Medical Research industry. The average price target is 6.00, with a high of 10.00 and a low of 4.00.

Score

Industry at a Glance

Previous score

9.33

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 6 analysts

Strong Buy

Current Rating

7.000

Target Price

+211.11%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Acumen Pharmaceuticals Inc

ABOS

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Acumen Pharmaceuticals Inc is 7.11, ranking 101 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 3.08 and the support level at 1.70, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.95

Change

0.16

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.020

Buy

RSI(14)

55.976

Neutral

STOCH(KDJ)(9,3,3)

31.230

Sell

ATR(14)

0.322

High Vlolatility

CCI(14)

4.776

Neutral

Williams %R

50.384

Neutral

TRIX(12,20)

1.246

Sell

StochRSI(14)

32.790

Buy

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

2.452

Sell

MA10

2.526

Sell

MA20

2.185

Buy

MA50

2.078

Buy

MA100

1.955

Buy

MA200

1.601

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Acumen Pharmaceuticals Inc is 7.00, ranking 86 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 75.57%, representing a quarter-over-quarter decrease of 12.69%. The largest institutional shareholder is The Vanguard, holding a total of 1.65M shares, representing 2.73% of shares outstanding, with 14.62% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

RA Capital Management, LP

14.93M

Hardie Robert D

3.45M

Sands Capital Ventures LLC

3.42M

PBM Capital Group, LLC

3.21M

Franklin Advisers, Inc.

2.31M

-24.54%

Fidelity Management & Research Company LLC

2.03M

-0.02%

The Vanguard Group, Inc.

Star Investors

1.65M

-2.24%

Knollwood Investment Advisory, LLC

1.63M

Alyeska Investment Group, L.P.

939.60K

Adar1 Capital Management LLC

891.18K

-2.73%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Acumen Pharmaceuticals Inc is 2.42, ranking 229 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.27. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.